CONFERENCES

    European Society of Cardiology

    European Society of Cardiology helds various events that focuse on cardiovascular research and treatment in Europe, with topics ranging from diagnostics to prevention. Those conference are aimed at cardiologists, researchers, and other professionals involved in the study and treatment of cardiovascular disease in Europe, and provide a forum for sharing knowledge and collaborating on new approaches to diagnosis and therapy.

    ESC Heart & Stroke 2020

    Date

    Jan 24, 2020 - Jan 25, 2020

    Location

    Barcelona, Spain

    This 2-day meeting of the ESC Council on Stroke aims to up-date current knowledge and communicate future perspectives on stroke diagnosis and treatment to a broad audience including physicians, specialist nurses, clinical researchers, and young investigators from several specialities (Cardiology, Neurology, vascular surgeons, etc). The meeting focuses in the live and interactive discussion of clinical cases facilitating the participation of both the senior and young clinical experts.

    23rd Cardiology Update Course 2019

    Date

    Feb 16, 2019 - Feb 20, 2019

    Location

    Davos, Switzerland

    Cardiology Update belongs to the major meetings in the field of cardiology in Europe. The course is a joint educational program from the Zurich Heart House / University of Zurich, the European Society of Cardiology (ESC), the Brigham and Women’s Hospital in Boston and the University of Michigan School of Medicine. A distinguished international teaching faculty contributes to an outstanding programme on latest scientific and therapeutic developments as well as on new intervention and treatment strategies in cardiology.

    See related posters

    Eurothrombosis 2018

    Date

    Oct 04, 2018 - Oct 06, 2018

    Location

    Barcelona, Spain

    Bringing together almost 250 attendees from 36 countries, this conference aims to enhance the knowledge of thrombosis in clinical cardiology.

    See related posters

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.